Samuel Gordon,Katarzyna Klas,Marcin Waligora
Samuel Gordon
Introduction: Drug repurposing is the strategy of identifying novel therapeutic uses for existing, unapproved, or failed drugs distinct from their original indications. Given the unique nature of repurposing, clinical tri...
Potential beneficial effect of treatment with PCSK9 inhibitors on vascular endothelial dysfunction: a systematic review and meta-analysis [0.03%]
PCSK9抑制剂治疗对血管内皮功能障碍潜在有益作用的系统评价和meta分析
Christina Antza,Panagiota Anyfanti,Charalampia Savva et al.
Christina Antza et al.
Introduction: PCSK9 inhibitors (PCSK9i) are at the center of research for their pleiotropic effects. The aim of this study is to systematically review the literature for their effect on vascular endothelial dysfunction. ...
Immunotherapy in limited-stage small cell lung cancer: riding the ADRIATIC wave toward precision [0.03%]
局限性小细胞肺癌的免疫治疗：朝着精准医疗的方向前进——ADRIATIC之旅
Serena Eccher,Adele Bonato,Marco Sposito et al.
Serena Eccher et al.
Martina Maurelli,Andrea Danese,Paolo Gisondi et al.
Martina Maurelli et al.
Introduction: Biosimilars have emerged as a key strategy to improve access to biologic therapies in moderate-to-severe psoriasis, addressing long-standing limitations related to treatment costs and availability. ...
Developing treatment strategies to optimize outcomes in patients with psoriatic arthritis [0.03%]
优化银屑病关节炎患者治疗策略以改善预后
Fadi Kharouf,Aiman Arraf,Vinod Chandran
Fadi Kharouf
Introduction: Achieving sustained remission in psoriatic arthritis (PsA) remains challenging despite the availability of multiple biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). Heterog...
Predictive and prognostic factors for immunotherapy response in head and neck squamous cell carcinoma: a narrative review [0.03%]
头颈鳞癌免疫治疗反应的预测和预后因素：综述性研究
Concetta Calabrò,Giuseppe De Palma,Tarik Gheit et al.
Concetta Calabrò et al.
Introduction: Immune checkpoint inhibitors (ICIs) have reshaped the therapeutic landscape of head and neck squamous cell carcinoma (HNSCC). However, only a subset of patients derives durable benefit, highlighting the need...
Integrating homologous recombination deficiency and replication stress: converging strategies unlocking new frontiers in precision oncology [0.03%]
同源重组缺陷与复制压力的整合：解锁精准肿瘤学新前沿的汇合策略
Tugba Y Ozmen,Connor M Frankston,Matthew J Rames et al.
Tugba Y Ozmen et al.
Introduction: Homologous recombination (HR) deficiency (HRD) and replication stress (RS) are increasingly recognized as interconnected hallmarks of genomic instability in cancer, offering promising avenues for therapeutic...
A pharmacological profile of pacritinib for the treatment of myelofibrosis [0.03%]
治疗骨髓纤维化的pacritinib的药理学特性分析
Hannah Goulart,Lucia Masarova,Naveen Pemmaraju et al.
Hannah Goulart et al.
Introduction: Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by splenomegaly, constitutional symptoms, progressive cytopenias, and limited overall survival. While Janus kinase (JAK) inhibitors h...
PD-1/PD-L1 for prostate cancer: from clinical trials to practice [0.03%]
PD-1/PD-L1在前列腺癌中的应用：从临床试验到临床实践
Aaron Holmes,Tobechukwu Okobi,Abdul Baseet Arham et al.
Aaron Holmes et al.
Introduction: A growing number of malignancies have shown favorable responses to immune checkpoint inhibitors (ICI), most commonly anti-PD-(L)1 antibodies. However, prostate cancer has been associated with mostly unfavora...
A tiered decisional framework for genetic epileptic syndromes with or without encephalopathies: from standard care to investigational strategies [0.03%]
遗传性癫痫性综合征（伴或不伴有脑病）的分层决策框架：从常规护理到研究策略
Lorenzo Perilli,Alessandro Ferretti,Antonella Riva et al.
Lorenzo Perilli et al.
Introduction: Developmental and epileptic encephalopathies (DEEs), epilepsy-associated neurodevelopmental disorders (NDD), and epileptic syndromes with or without encephalopathy (ES±E) share overlapping genetic architect...